Patents by Inventor Denis Francois Hochstrasser
Denis Francois Hochstrasser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9028825Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.Type: GrantFiled: July 14, 2006Date of Patent: May 12, 2015Assignee: Universite de GeneveInventors: Denis Francois Hochstrasser, Jean-Charles Sanchez
-
Patent number: 8772042Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: GrantFiled: May 2, 2011Date of Patent: July 8, 2014Assignee: Bayer Intellectual Property GmbHInventors: Özkan Yalkinoglu, Gerhard König, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Publication number: 20120016205Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: ApplicationFiled: May 2, 2011Publication date: January 19, 2012Applicant: BAYER HEALTHCARE AGInventors: Õzkan Yalkinoglu, Gerhard Kõnig, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Patent number: 7767401Abstract: Stroke is diagnosed in a subject by determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid taken from the subject.Type: GrantFiled: August 16, 2004Date of Patent: August 3, 2010Assignee: Electrophoretics LimitedInventors: Pierre Lescuyer, Denis Francois Hochstrasser, Jean-Charles Sanchez, Laure Allard, Elisabeth Guillaume
-
Patent number: 7754436Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using a anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.Type: GrantFiled: September 28, 2006Date of Patent: July 13, 2010Assignee: Electrophorectics LimitedInventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmerman
-
Patent number: 7368247Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using a specific antibody thereto. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-1 or CK-MB as a marker, also to be carried out.Type: GrantFiled: September 10, 2002Date of Patent: May 6, 2008Assignee: Universite De GeneveInventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmermann, Elisabeth Guillaume
-
Patent number: 7144705Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.Type: GrantFiled: June 7, 2002Date of Patent: December 5, 2006Assignee: ElectroPhoretics LimitedInventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmerman
-
Patent number: 6787330Abstract: Polypeptides which have been separated by gel electrophoresis can be identified or characterized by a procedure which has two main stages. In the first stage the gel is digested with a polypeptide-cleaving agent such as an enzyme. This produces mainly large fragments which, in the second stage are electroblotted through a hydrophilic membrane on which is immobilized another polypeptide-cleaving reagent such as an enzyme onto a hydrophobic member, typically a membrane, e.g. of PVDF. The resulting fragments, usually peptides, are identified, preferably by MALDI-TOF MS, or a property may be determined, e.g. by interaction with an antibody.Type: GrantFiled: July 18, 2001Date of Patent: September 7, 2004Assignee: University of GenevaInventors: Willy Vincent Bienvenut, Denis Francois Hochstrasser, Jean-Charles Sanchez
-
Publication number: 20040171026Abstract: Transmissible spongiform encephalopathy (TSE) is diagnosed in a subject by using mass spectrometry to observe a polypeptide in a sample of body fluid taken from the subject. The polypeptide is differentially contained in the body fluid of TSE-infected subjects and non-infected subjects, and has a molecular weight in the range of from 1000 to 100000.Type: ApplicationFiled: October 28, 2003Publication date: September 2, 2004Inventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Elisabeth Guillaume
-
Patent number: 6632339Abstract: Polypeptides which have been separated by gel electrophoresis can be identified by electroblotting them through a “sandwich” comprising in order: a) the separation gel; b) at least one hydrophilic membrane, e.g. of carboxyl-modified PVDF, on which is immobilized at least one reagent capable of cleaving a polypeptide, e.g. trypsin; c) a hydrophobic layer, typically a membrane, e.g. of PVDF. Preferably a biased alternating current or discontinuous direct current is used for electroblotting. The resulting fragments, usually peptides, are identified, preferably by MALDI-TOF MS.Type: GrantFiled: June 15, 2000Date of Patent: October 14, 2003Assignee: University of GenevaInventors: Willy Vincent Bienvenut, Denis Francois Hochstrasser
-
Publication number: 20030157580Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for TSEs, especially CJD. The invention provides a diagnostic assay for either of these markers, preferably by enzyme immunoassay using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish CJD from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.Type: ApplicationFiled: September 10, 2002Publication date: August 21, 2003Inventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmermann, Elisabeth Guillaume
-
Publication number: 20030100038Abstract: Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.Type: ApplicationFiled: June 7, 2002Publication date: May 29, 2003Inventors: Denis Francois Hochstrasser, Jean-Charles Sanchez, Catherine Gabrielle Zimmerman
-
Publication number: 20020150569Abstract: A method of diagnosis of solid epithelial tumours or other abnormalities such as rectal colitis, which comprises size-separating stroma from epithelial cells, separating the epithelial cells from most of the other tissue still present, by reacting the tissue with a monoclonal antibody specific for epithelial cells, collecting the reacted cells bound to the antibody and releasing them from the antibody, whereby the sample contains at least 90 percent epithelial cells by volume of the total tissue of the sample and comparing at least one phenotypic or genotypic characteristic of the sample with corresponding normal epilthelial cellsType: ApplicationFiled: April 10, 2000Publication date: October 17, 2002Inventors: DENIS FRANCOIS HOCHSTRASSER, MARK ANDRE REYMOND, MIGUEL ANGEL PEINADO
-
Patent number: 6221626Abstract: Polypeptides separated on a gel are identified by cleaving the separated polypeptides with an immobilized cleaving reagent such as an enzyme, and transferring the fragments to a hydrophobic collection layer where they are analyzed. A hydrophilic membrane containing an immobilized protease such as trypsin is provided between an electrophoresis gel and a hydrophobic membrane to form an electroblotting “sandwich”. Polypeptides separated on the gel by electrophoresis are electroblotted from the gel through the hydrophilic membrane where they are cleaved by the protease into fragments, and the fragments are collected on the hydrophobic membrane where they are identified such as by MALDI-TOF MS analysis. From identification of the fragments, the polypeptide from which they came is identified. The hydrophilic membrane may be provided with functional groups to which the protease is immobilized by covalent bonding.Type: GrantFiled: June 30, 1998Date of Patent: April 24, 2001Assignee: University of GenevaInventors: Willy Vincent Bienvenut, Denis Francois Hochstrasser